B
OVID icon

Bailard’s Ovid Therapeutics OVID Stock Holding History

Bailard’s Portfolio OVID Stock Details OVID Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-12,600
Closed -$38.4K – 793
2024
Q1 		$38.4K Hold
12,600
– – ﹤0.01% 729
2023
Q4 		$40.6K Hold
12,600
– – ﹤0.01% 702
2023
Q3 		$48.4K Hold
12,600
– – ﹤0.01% 689
2023
Q2 		$41.3K Hold
12,600
– – ﹤0.01% 682
2023
Q1 		$32.5K Hold
12,600
– – ﹤0.01% 708
2022
Q4 		$23.4K Buy
12,600
+800
+7% +$1.36K ﹤0.01% 700
2022
Q3 		$22K Buy
+11,800
New +$24.7K ﹤0.01% 658
2022
Q1 		– Sell
-47,948
Closed -$154K – 791
2021
Q4 		$154K Buy
+47,948
New +$164K ﹤0.01% 702

Other funds holding OVID

TPC
Takeda Pharmaceutical Company Tokyo, Japan $16.4M AUM 195.92% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
MAP
Madison Avenue Partners New York $2.3B AUM 115.82% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
KCM
Kennedy Capital Management St Louis, Missouri $4.72B AUM 36.69% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Bailard's OVID Position: Q2 2024 in Review

Bailard sold out of Ovid Therapeutics (OVID) in Q2 2024, closing a stake of 12,600 shares — an estimated $38.4K sold.

Bailard first reported a position in OVID in Q4 2021 and held it in 8 quarters. The position peaked at $154K in Q4 2021. 74 funds tracked by Wall St. Rank hold OVID as of Q2 2024.

  • Bailard reported no remaining Ovid Therapeutics position as of Q2 2024 after selling out during the quarter.
  • Bailard sold 12,600 Ovid Therapeutics shares in Q2 2024, an estimated $38.4K.
  • Bailard first reported a position in Ovid Therapeutics in Q4 2021 and held it in 8 quarters.
  • Bailard's Ovid Therapeutics position peaked at $154K in Q4 2021.
  • 74 funds tracked by Wall St. Rank held Ovid Therapeutics as of Q2 2024.

Based on Bailard's 13F filing for Q2 2024, filed 25 Jul 2024.